Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14072914 | 0.81 | APEX1 (0.49) | ALOX5APEX1POLBKMT2AL3MBTL1 | |
| SCHEMBL14072951 | 0.79 | ALOX5 (0.44) | TAS1R3TAS1R1ALOX5APEX1POLB | |
| SCHEMBL14072947 | 0.76 | TAS1R3 (0.40) | TAS1R3TAS1R1ALOX5KMT2AMEN1 | |
| SCHEMBL13181122 | 0.76 | TAS1R3 (0.53) | TAS1R3TAS1R1APEX1HTTPOLB | |
| SCHEMBL12848813 | 0.68 | CA1 (0.35) | ALOX5POLBMAPTHSD17B10TSHR | |
| SCHEMBL20156405 | 0.68 | PKM (0.45) | PKMHTTPOLBKMT2AL3MBTL1 | |
| SCHEMBL4298346 | 0.66 | ALOX5 (0.48) | ALOX5KMT2AMEN1CYP3A4MAPT | |
| SCHEMBL27584559 | 0.65 | GABRA1 (0.53) | PKMHTTALDH1A1GAAHSP90AA1 | |
| SCHEMBL27898710 | 0.65 | FABP3 (0.62) | PKMKMT2AMEN1CYP3A4PTGS1 | |
| Cadaverine Tartrate SCHEMBL950255 | 0.65 | KDM4E (0.37) | ALOX5POLBKMT2AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178826-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | MERCK SHARP & DOHME (US) | 2017-05-17 | — | — | EP | claimed |
| US-8519168-B2 | Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | claimed |
| US-20110160469-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-06-30 | — | — | US | claimed |
| EP-2178826-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | SCHERING CORPORATION (US) | 2010-04-28 | — | — | EP | claimed |
| WO-2009005801-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | claimed |
| US-8519168-B2 | Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519168-B2 | Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519168-B2 | Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110160469-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110160469-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110160469-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110009482-A1 | METHODS OF TREATING COPD | SCHERING CORPORATION (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2009005801-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005801-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005802-A1 | PROCESS FOR CONTROLLED CRYSTAL SIZE IN 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005802-A1 | PROCESS FOR CONTROLLED CRYSTAL SIZE IN 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20080045489-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | PHARMACOPEIA, INC. FORMERLY KNOWN AS PHARMACOPEIA DRUG DISCOVERY, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045489-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | PHARMACOPEIA, INC. FORMERLY KNOWN AS PHARMACOPEIA DRUG DISCOVERY, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045489-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | PHARMACOPEIA, INC. FORMERLY KNOWN AS PHARMACOPEIA DRUG DISCOVERY, INC. | 2008-02-21 | — | — | US | disclosed |
| WO-2008005570-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160469-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | CCL2, CCR1, CXCR1 | PKM 2934/4885TAS1R3 4341/4885TAS1R1 4259/4885 |
| US-20080045489-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | CCR5, CXCR3, CCR2 | PKM 3325/4885TAS1R3 2765/4885TAS1R1 2979/4885 |
| US-20110009482-A1 | METHODS OF TREATING COPD | CXCR2, AGTR2, LTB4R2 | PKM 3380/4885TAS1R3 4319/4885TAS1R1 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.